Other substances

Magnesium

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
14
 AI-suggested references
3
 Clinical trials

 

Supporting references

Link Tested on Impact factor Notes Publication date
A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients.
Preprint Cohort study 		Patients

used as vitamin D3 1000 IU OD, magnesium 150mg OD and vitamin B12 500mcg OD upon admission when not requiring oxygen therapy

 Jun/10/2020

AI-suggested references

Link Publication date
Promising therapeutic approach for SARS-CoV-2 infection by using a rutin-based combination therapy.
May/24/2022
Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19
Apr/28/2021
The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19.
Apr/06/2021
Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19)
Jan/22/2022
Enhanced Antiviral Function of Magnesium Chloride-Modified Heparin on a Broad Spectrum of Viruses.
Sep/17/2021
Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in MAGT1 Deficiency
Nov/24/2021
Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection
Feb/04/2021
Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study.
Mar/15/2021
WELPSA: A natural catalyst of alkali and alkaline earth metals for the facile synthesis of tetrahydrobenzo[b]pyrans and pyrano[2,3-d]pyrimidinones as inhibitors of SARS-CoV-2
Jun/30/2021
Magnesium treatment on methylation changes of transmembrane serine protease 2 (TMPRSS2).
May/07/2021
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole
Jul/02/2020
Nebulized fentanyl for respiratory symptoms in patients with COVID-19 (ventanyl trial)
Jan/29/2022
[Salvianolic acid B and its magnesium salt inhibit SARS-CoV-2 infection of Vero-E6 cells by blocking spike protein-mediated membrane fusion].
Dec/16/2021
Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit
May/21/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04621071 Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19 Completed Not Applicable Jan/12/2021 Oct/12/2021
  • Alternative id - 2021-3700
  • Interventions - Dietary Supplement: Probiotics (2 strains 10x10^9 UFC)|Dietary Supplement: Placebo (potato starch and magnesium stearate)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CIUSSS de L'Estrie-CHUS Hospital, Sherbrooke, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 17
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Duration of symptoms of the COVID-19|Severity of the COVID-19|Evolution of oral and fecal microbiota
NCT04941703 "CHANGE COVID-19 Severity" Recruiting Phase 1|Phase 2 Nov/04/2021 Jun/30/2024
  • Alternative id - 210598
  • Interventions - Drug: Magnesium Citrate plus probiotic
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Change in COVID Ordinal Outcome Scale
NCT04716985 Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care Recruiting Not Applicable Jan/22/2021 May/22/2023
  • Alternative id - 2020-A03137-32
  • Interventions - Dietary Supplement: MOLECULAR HYDROGEN|Dietary Supplement: PLACEBO MAGNESIUM
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Timc-Imag (Umr5525 Uga-Cnrs), Grenoble, France|Casablanca center, Casablanca, Morocco|Public Health Center, Sremska Kamenica, Serbia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 580
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change in the incidence rate of the onset of clinical worsening|Assessment of tolerance|Assessment of compliance|Assessment of medium-long term dyspnea symptoms|Assessment of medium-long term fatigue symptoms|Assessment of oximetry symptoms|Assessment of quality of life|Assesment of sleep quality|Assessment of care consumption|Assessment of blind treatment|Assessment of COVID-19 contact cases|Assessment of risk factors|Analysis of older patients|Assessment of pain
Export (.csv)